Funded in part by Amarin Corporation, Amarin Pharma
Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes
Mason RP, Jacob RF, Shrivastava S, Sherratt SCR, Chattopadhyay A
Biochimica et biophysica acta · 129 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- In vitro/mechanistic study (classified by our AI screen)
- Studied in
- Cells or lab samples
- Main outcome
- Mechanisms only
Who paid for it
- Funding
- Industry funded
- Company
- Amarin Corporation
- Government
- Department of Science and Technology, Ministry of Science and Technology, India
- Government
- Council of Scientific and Industrial Research, India
- Company
- Amarin Pharma
Based on 4 listed funder(s).
Publication
- Published
- 2016-10-09 · Biochim Biophys Acta · vol. 1858 · issue 12 · pp. 3131–3140
- Publisher
- Elsevier BV
- Cited
- 177 citations · more than 98% of similar papers · 7.7× the field average
- Impact
- Top 10% most cited in its field
- References
- 76 works
- Access
- Open access (hybrid journal) · CC-BY
- Research areas
- Fatty Acid Research and Health · Cholesterol and Lipid Metabolism · Lipid metabolism and biosynthesis
- Keywords
- Bilayer, Eicosapentaenoic acid, Membrane, Membrane fluidity, Lipid bilayer, Cholesterol, Biophysics, Chemistry, Internal medicine, Materials science, Medicine, Biochemistry, Fatty acid, Biology, Polyunsaturated fatty acid
- MeSH
- humans, cholesterol, docosahexaenoic acids, eicosapentaenoic acid, lipid bilayers, membrane fluidity, dose-response relationship, drug, atherosclerosis
5 authors
From US, IN
- Richard Preston Mason · correspondingBrigham and Women's Hospital; Harvard University
- Robert Francis Jacob
- Sandeep Kumar ShrivastavaCentre for Cellular and Molecular Biology
- Samuel C. R. Sherratt
- Amitabha ChattopadhyayCentre for Cellular and Molecular Biology
Abstract
Cholesterol crystalline domains characterize atherosclerotic membranes, altering vascular signaling and function. Omega-3 fatty acids reduce membrane lipid peroxidation and subsequent cholesterol domain formation. We evaluated non-peroxidation-mediated effects of eicosapentaenoic acid (EPA), other TG-lowering agents, docosahexaenoic acid (DHA), and other long-chain fatty acids on membrane fluidity, bilayer width, and cholesterol domain formation in model membranes. In membranes prepared at 1.5:1 cholesterol-to-phospholipid (C/P) mole ratio (creating pre-existing domains), EPA, glycyrrhizin, arachidonic acid, and alpha linolenic acid promoted the greatest reductions in cholesterol domains (by 65.5%, 54.9%, 46.8%, and 45.2%, respectively) compared to controls; other treatments had modest effects. EPA effects on cholesterol domain formation were dose-dependent. In membranes with 1:1 C/P (predisposing domain formation), DHA, but not EPA, dose-dependently increased membrane fluidity. DHA also induced cholesterol domain formation without affecting temperature-induced changes in-bilayer unit cell periodicity relative to controls (d-space; 57Å-55Å over 15-30°C). Together, these data suggest simultaneous formation of distinct cholesterol-rich ordered domains and cholesterol-poor disordered domains in the presence of DHA. By contrast, EPA had no effect on cholesterol domain formation and produced larger d-space values relative to controls (60Å-57Å; p<0.05) over the same temperature range, suggesting a more uniform maintenance of lipid dynamics despite the presence of cholesterol. These data indicate that EPA and DHA had different effects on membrane bilayer width, membrane fluidity, and cholesterol crystalline domain formation; suggesting omega-3 fatty acids with differing chain length or unsaturation may differentially influence membrane lipid dynamics and structural organization as a result of distinct phospholipid/sterol interactions.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.